Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Sangamo Therapeutics (SGMO) EBT Margin (2016 - 2025)

Historic EBT Margin for Sangamo Therapeutics (SGMO) over the last 17 years, with Q3 2025 value amounting to 6039.76%.

  • Sangamo Therapeutics' EBT Margin fell 60615400.0% to 6039.76% in Q3 2025 from the same period last year, while for Sep 2025 it was 343.61%, marking a year-over-year decrease of 857200.0%. This contributed to the annual value of 169.74% for FY2024, which is 205600.0% down from last year.
  • Latest data reveals that Sangamo Therapeutics reported EBT Margin of 6039.76% as of Q3 2025, which was down 60615400.0% from 109.03% recorded in Q2 2025.
  • Over the past 5 years, Sangamo Therapeutics' EBT Margin peaked at 21.78% during Q3 2024, and registered a low of 10185.24% during Q1 2024.
  • Over the past 5 years, Sangamo Therapeutics' median EBT Margin value was 195.35% (recorded in 2022), while the average stood at 1905.37%.
  • Its EBT Margin has fluctuated over the past 5 years, first tumbled by -101987400bps in 2024, then soared by 100185000bps in 2025.
  • Sangamo Therapeutics' EBT Margin (Quarter) stood at 166.66% in 2021, then fell by -14bps to 189.92% in 2022, then plummeted by -1462bps to 2966.06% in 2023, then surged by 88bps to 366.51% in 2024, then tumbled by -1548bps to 6039.76% in 2025.
  • Its EBT Margin was 6039.76% in Q3 2025, compared to 109.03% in Q2 2025 and 473.48% in Q1 2025.